肺癌患者癌组织和血浆p16基因甲基化的检测及其临床意义

目的研究非小细胞肺癌患者癌组织和血浆p16基因甲基化及其临床意义。方法选择120例非小细胞肺癌患者,用巢式甲基化特异性聚合酶链反应法检测其肺癌组织、癌旁正常组织和外周血血浆p16基因的甲基化,并对120例正常对照组血浆样品进行p16基因甲基化检测,各组检测结果进行比较。结果肺癌组织p16基因甲基化率44.2%,高于癌旁组织的11.7%(P0.01);非小细胞肺癌患者血浆样品中p16基因甲基化检测率为32.5%,对照组血浆未检测到p16基因甲基化(P0.01);肺癌患者血浆样品与癌组织p16基因甲基化检出率比较差异无显著性(P0.05);患者血浆样品与癌旁组织p16基因甲基化检出率比较差异有显著性(P0.01)。结论肺癌患者癌组织和血浆样本p16基因甲基化的检测都为肺癌的早期筛查和诊断提供了有价值的参考信息。

Methylation of p16 gene in plasma and tissues from non-small cell lung cancer patients

Objective To detect methylation of p16 gene in plasma and tissues from NSCLC patients,and to evaluate the clinical significance.Methods The methylation of p16 gene in DNA from 120 non-small cell lung cancer tissues and corresponding nomalignant tissues were tested with the methods of the methylation-specific PCR（MSP）,and Methylation of p16 gene was tested by MSP among the plasma from 120 cases of NSCLC and the plasma from 120 cases of controls.Results The total frequency of p16 methylation was 44.2% in lung cancer tissues,significantly higher than that in the nomalignant tissues 11.7%（P〈0.01）;32.5% of the plasma from 120 cases of NSCLC showed hypermethylation for p16 gene,whereas no methylated p16 gene were found in plasma from the norml controls（P〈0.01）.The methylation of p16 gene in DNA did not exhibit the obvious difference between the cancer tissues and the plasma of NSCLC（P〉0.05）.The methylation of p16 gene in DNA exhibited the obvious difference between the nomalignant tissues and the plasma of NSCLC（P〈0.01）.Conclusion Detection of the methylation of p16 gene in plasma and lung cancer tissues from NSCLC patients might offer an effective means for the earlier diagnosis of the malignancy.